Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F4ZUT
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,010
Award facts
- Contract value 100% obligated
- $13,009.74 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $13,009.74 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed-price contract. The award was made on January 22, 2026, with an ultimate completion date of January 23, 2026, and represents a non-competitive set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, with the place of performance located at its corporate office in Conshohocken, PA. The company is a subsidiary of Cencora, Inc., which operates under the AmerisourceBergen doing-business-as name.
This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), a $999,999,999.00 vehicle running through December 2026 that provides comprehensive global pharmaceutical support to military healthcare systems. The IDC enables the company to supply a broad range of pharmaceutical products, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency operations, the U.S. Coast Guard, and other government healthcare entities. Dupixent (dupilumab) is a prescription biologic medication used to treat atopic dermatitis, asthma, and other allergic conditions, making this delivery order consistent with the subsidiary's portfolio of specialty pharmaceutical products supplied to federal military and veteran healthcare programs.
Quick answers
Who was awarded contract SPE2DR26F4ZUT?
SPE2DR26F4ZUT was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F4ZUT worth?
The government has obligated $13,010 on SPE2DR26F4ZUT.
Is contract SPE2DR26F4ZUT an order under another contract?
Yes. SPE2DR26F4ZUT is a delivery order under SPE2DR25D2010, an indefinite delivery contract.
Was contract SPE2DR26F4ZUT competed?
The extent of competition for SPE2DR26F4ZUT was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award